Pharmacists in Independence, OR Accepting Medicare
2 Pharmacists found. Showing 1 - 2
 Terry J Crowder, RPH Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1357 Monmouth St, Independence, OR 97351 Phone: 503-828-2195 |
Andrew Vanderwall Pharmacist Medicare: Not Enrolled in Medicare Practice Location: 1357 Monmouth St, Independence, OR 97351 Phone: 503-838-2195 Fax: 503-838-3129 |
News Archive
Long-term, regular acetaminophen use may be associated with lower prostate cancer risk
A new study from American Cancer Society researchers finds use of 30 tablets a month or more of acetaminophen for five or more years was associated with an estimated 38% lower risk of prostate cancer. The study appears in Cancer Epidemiology, Biomarkers and Prevention and is one of only two studies of prostate cancer to date that have examined the association with acetaminophen use that was both long-term and regular.
Researchers explore how toxic protein clusters linked to Parkinson's disrupt brain cells
Researchers have glimpsed how the toxic protein clusters that are associated with Parkinson's Disease disrupt the membranes of healthy brain cells, creating defects in the cell walls and eventually causing a series of events that induce neuronal death.
New game theory approach helps identify bacterial antibiotic resistance
Washington State University researchers have developed a novel way to identify previously unrecognized antibiotic-resistance genes in bacteria.
Cord Blood America announces retirement of $1.6 million in debt since July 2009
Cord Blood America, Inc. (OTC Bulletin Board: CBAI), the umbilical cord blood stem cell preservation company (http://www.cordblood-america.com ) focused on bringing the life saving potential of stem cells to families nationwide and internationally, said today that it has retired $1.6 million in debt since July 2009. The Company previously announced it retired $5 million in debt in the first half of 2009.
Edimer doses first XLHED-affected neonate in Phase 2 trial of EDI200
Edimer Pharmaceuticals, a biotechnology company focused on developing an innovative therapy for the rare genetic disorder X-linked Hypohidrotic Ectodermal Dysplasia (XLHED), today announced the enrollment and completed dosing of the first XLHED-affected neonate in a Phase 2 trial of EDI200, the company's novel, proprietary, recombinant protein.
› Verified 8 days ago